Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy
✍ Scribed by Antonio Carvajal-Rodríguez; Keith A. Crandall; David Posada
- Publisher
- Elsevier Science
- Year
- 2007
- Tongue
- English
- Weight
- 568 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1567-1348
No coin nor oath required. For personal study only.
✦ Synopsis
We studied the relationship between recombination and the fixation time of multiple drug resistance mutations after HIV-1 drug therapy, under a set of different realistic scenarios. We have generalized a previous model by Bretscher et al. [Bretscher, Althaus, Muller, Bonhoeffer, 2004. Recombination in HIV and the evolution of drug resistance: for better or for worse? Bioessays 26(2), 180-188] in order to explore different implementations of phenotypic mixing and more realistic demographic and selective regimes. Using computer simulations we show that the effect of recombination on the evolution of drug resistance depends strongly on the intensity of selection, as well as on the viral population size. Under the high selection pressure expected during antiretroviral therapy, the strength of the Hill-Robertson effect increases and recombination favors the evolution of resistance under a wide range of population sizes, independently of the sign of the epistatic interaction. Our results suggest that recombination plays an important role in the evolution of drug resistance in HIV-1 under various realistic scenarios. These findings could be taken into account in order to develop optimal HIV-1 drug treatments.
📜 SIMILAR VOLUMES
## Abstract This study reports the analysis of human immunodeficiency virus type 1 (HIV‐1) protease (PR) and reverse transcriptase (RT) coding sequences from 136 HIV‐1‐infected subjects from Chile, 66 (49%) of them under antiretroviral (ARV) treatment. The prevalence of mutations conferring high or
## Abstract Resistance to available antiretroviral (ARV) agents is of increasing concern, and development of novel agents that address this problem has been identified as a major public health priority. As ARV resistance becomes more prevalent with extended use of existing agents, individuals with